Current clinical trials in Hodgkin's disease

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Hodgkin's disease (HD) treatment has advanced with polychemotherapy and radiation, significantly improving cure rates.
• Current strategies balance treatment efficacy with patient toxicity, especially in early-stage HD where cure rates approach 90%.
• Advanced-stage HD requires improved complete remission and survival rates, as current regimens show limitations.

Purpose of the Study:

• To summarize current treatment concepts for early, intermediate, and advanced stage Hodgkin's disease.
• To discuss strategies for balancing cure rates and treatment toxicity.
• To highlight novel therapeutic regimens and the need for risk-adapted therapy.

Main Methods:

• Review of current treatment strategies for Hodgkin's disease across different stages.
• Discussion of established polychemotherapy regimens (M(C)OPP, ABVD) and novel protocols (Stanford V, BEACOPP).
• Exploration of risk stratification for personalized treatment approaches.

Main Results:

• Early-stage HD achieves high cure rates (~90%), with focus shifting to toxicity reduction.
• Advanced-stage HD requires better complete remission and survival rates; efficacy of post-chemotherapy radiotherapy is uncertain.
• Novel intensified regimens like Stanford V and BEACOPP aim for improved tumor control.

Conclusions:

• Risk-adapted therapy is crucial for optimizing Hodgkin's disease treatment, potentially reducing doses in early stages.
• Identification of high-risk groups will enable stratification into more aggressive, effective regimens.
• Ongoing trials focus on enhancing tumor control and minimizing long-term toxicity in Hodgkin's disease management.